The Series B extension brings Atavistik Bio’s Series B financing to $160 million. The startup’s lead program is in development for hereditary hemorrhagic telangiectasia (HHT), an inherited bleeding disorder.
Atavistik Bio is one of several companies discovering and developing drugs that work by allostery, binding to less obvious sites of a target protein. Acting CEO John Josey said the startup aims to stand apart with its focus on understanding metabolic interactions, a path less trodden by others in allosteric drug discovery.
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!